ALLO-605 for Neoplasms, Plasma Cell

Phase-Based Progress Estimates
Texas Transplant Institute, San Antonio, TX
Neoplasms, Plasma Cell+2 More
ALLO-605 - Genetic
All Sexes
Eligible conditions

Study Summary

This study is evaluating whether a drug called ALLO605 can help treat multiple myeloma.

See full description

Eligible Conditions

  • Neoplasms, Plasma Cell
  • Relapsed Or Refractory Multiple Myeloma

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether ALLO-605 will improve 3 primary outcomes in patients with Neoplasms, Plasma Cell. Measurement will happen over the course of 28 days.

Month 12
Phase 2: To assess clinical efficacy of ALLO-605 as measured by overall response rate (ORR)
28 days
Phase 1: Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-605 that will determine MTD/MAD and select the recommended Phase 2 dose (RP2D) of ALLO-605.
30 days
Phase 1: Proportion of patients experiencing Dose Limiting Toxicities with ALLO-647 [administered in combination with fludarabine/cyclophosphamide administered prior to ALLO-605]

Trial Safety

Safety Estimate

1 of 3

Trial Design

1 Treatment Group

ALLO-605, ALLO-647
1 of 1
Experimental Treatment

This trial requires 136 total participants across 1 different treatment group

This trial involves a single treatment. ALLO-605 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

ALLO-605, ALLO-647
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months of study follow-up
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 12 months of study follow-up for reporting.

Closest Location

Texas Transplant Institute - San Antonio, TX

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Neoplasms, Plasma Cell or one of the other 2 conditions listed above. There are 6 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
The Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 is a measure of a person's ability to carry out everyday activities show original
activity People who have a disease must have some way to measure how active the disease is show original
Adequate hematologic, renal, liver, pulmonary, and cardiac functions
If you have a life expectancy of 3 months or more without treatment, you may be a good candidate for hospice care. show original
is required for enrollment People with relapsed or refractory MM will be enrolled in this study. show original
People must have received at least three prior lines of treatment for multiple myeloma in order to be eligible for this study. show original

Patient Q&A Section

What are the common side effects of allo-605?

"The most common side effect was fatigue, which occurred in almost half of participants treated with allo-605. Other common side effects included nausea and vomiting, diarrhea, headache, constipation, dry mouth, itchiness, rash, itching, insomnia, joint tenderness, abdominal pain, dyspepsia, dizziness, chest discomfort, anxiety, depression, shortness of breath, cough, muscle aches, weakness, and fever." - Anonymous Online Contributor

Unverified Answer

How many people get multiple myeloma a year in the United States?

"At least one case of MM should occur in about 1.5 cases per 100,000 US population each year. In all, at least 3 cases of MM occurred per 100,000 US population for every year between 2001 and 2010. The incidence and prevalence rates appear to be increasing, likely because of improved survival and increased exposure to exposures such as ionizing radiation and environmental toxins." - Anonymous Online Contributor

Unverified Answer

Is allo-605 safe for people?

"Though the safety profile for allo-605 appears similar to what has been seen with other agents used to treat multiple myeloma, the low rate of serious adverse events warrants further investigation." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for multiple myeloma?

"The 5 year survival rate was 24%, which is surprisingly low when compared to other cancers. Since the disease has a long latency period, it is important to detect and treat myeloma early." - Anonymous Online Contributor

Unverified Answer

What is allo-605?

"Allo-605 selectively targets ALK+ MM cells but not ALK- MM cells. This suggests that allo-605 may be a useful tool in the treatment of ALK+ MM." - Anonymous Online Contributor

Unverified Answer

How serious can multiple myeloma be?

"There is an increased risk for the development of cardiovascular disease in MM patients as compared to the general population, especially in those treated with bortezomib. It is therefore essential to oversee the patient's cardiovascular status during and after treatment with this drug. Further research is needed to understand the mechanisms involved in this association." - Anonymous Online Contributor

Unverified Answer

Is allo-605 typically used in combination with any other treatments?

"Allo-605 is a promising anticancer agent and deserves further investigation. It would not be suitable for broad application on multiple myeloma patients because of its low therapeutic index." - Anonymous Online Contributor

Unverified Answer

Can multiple myeloma be cured?

"Results from a recent paper presented here suggest that MM in remission can have a potentially favorable outcome if it were to remain in remission." - Anonymous Online Contributor

Unverified Answer

Does multiple myeloma run in families?

"We conclude that (1) genetic factors play an important role in the etiology of multiple myeloma; (2) the occurrence of the disease does not follow a Mendelian pattern of inheritance; and (3) familial aggregation results from environmental influences outside of the family." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of multiple myeloma?

"The majority of patients with multiple myeloma were diagnosed with an underlying plasma cell neoplasm (meaning they had one of the plasma cell tumors). Secondary multiple myeloma was more common than primary multiple myeloma." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets multiple myeloma?

"The average age at diagnosis was 64 years (range 53-85 years), with 45% diagnosed before the age of 70 years. There were no differences in survival based on gender, race, stage of disease, and number of bone lesions." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Neoplasms, Plasma Cell by sharing your contact details with the study coordinator.